AbbVie Inc

AbbVie Inc is a global biopharmaceutical company that develops, manufactures, and markets a range of therapeutic products, primarily in the areas of immunology, oncology, neuroscience, and virology.

AbbVie is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Pharmaceuticals industry, with a confidence level of 0.92.

### Capital Structure and Liquidity AbbVie has a high debt-to-equity ratio of 9.24, indicating a capital structure heavily reliant on debt financing. The company's cash and equivalents of $18.07 billion are insufficient to cover its long-term debt of $74.00 billion, resulting in a negative net cash position. The current ratio of 0.94 suggests limited short-term liquidity, as current liabilities exceed current assets. The liquidity risk is rated as medium, reflecting the company's high leverage and limited cash reserves.

### Profitability and Returns AbbVie's profitability is modest, with a return on equity (ROE) of 17.1% and a return on assets (ROA) of 0.92%. The company's operating margin is 22.7% (calculated from operating income of $2.80 billion and revenue of $12.31 billion), which is below the median for the pharmaceutical industry. The gross margin of 66.7% (calculated from gross profit of $8.22 billion and revenue of $12.31 billion) is in line with industry norms. However, the company's net margin of 11.1% (calculated from net income of $1.37 billion and revenue of $12.31 billion) is relatively low, indicating significant operating and non-operating expenses.

### Segments and Geographic Exposure AbbVie's revenue is concentrated in a few therapeutic areas, with the majority derived from its immunology and oncology segments. The company's geographic exposure is broad, with significant revenue generated in North America, Europe, and Asia-Pacific. However, the company's reliance on a few key products, such as Humira, exposes it to revenue concentration risk.

### Growth Trajectory AbbVie's revenue growth is expected to remain flat in the current fiscal year, with a slight decline in the next fiscal year. The company's capital expenditure of -$193 million indicates a reduction in investment in new projects. The free cash flow of $490 million is modest, limiting the company's ability to reinvest in growth opportunities.

### Risk Factors The company faces medium liquidity risk due to its high debt levels and limited cash reserves. The dilution risk is rated as low, with no significant dilution expected in the near term. The key risk flag is the negative net cash position, which could impact the company's ability to meet its debt obligations.

### Recent Events Recent filings and transcripts indicate that AbbVie is focusing on its pipeline of new products and the potential for new drug approvals. The company has also been active in mergers and acquisitions to expand its therapeutic portfolio.

Key takeaways

• AbbVie has a high debt-to-equity ratio of 9.24, indicating a capital structure heavily reliant on debt financing.
• The company's return on equity (ROE) is 17.1%, which is relatively high but not exceptional for the pharmaceutical industry.
• AbbVie's revenue is concentrated in a few therapeutic areas, exposing it to revenue concentration risk.
• The company's liquidity risk is rated as medium, reflecting its high leverage and limited cash reserves.
• AbbVie's revenue growth is expected to remain flat in the current fiscal year, with a slight decline in the next fiscal year.
• ---
• ## RATIONALES
• ```json

• Net cash is negative after subtracting total debt.